咪达唑仑(Midazolam) - 药物靶点：GABAA receptor_在研适应症：癫痫，癫痫持续状态，镇静_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Midazolam (Proximagen)、Midazolam intranasal、Midazolam intranasal spray

+ [17]

靶点

GABAA receptor

作用机制

GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂)

治疗领域

神经系统疾病其他疾病肿瘤+ [3]

在研适应症

癫痫癫痫持续状态镇静+ [5]

非在研适应症

急性反复发作晚期非小细胞肺癌ALK阳性实体瘤+ [12]

原研机构

在研机构

+ [9]

非在研机构

Hoffmann-La Roche, Inc.

Takeda Pharmaceutical Co., Ltd.UCB Biopharma SRL

+ [9]

最高研发阶段批准上市

首次获批日期

日本 (1988-03-29),

麻醉

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)、优先审评 (中国)

登录后查看首次获批时间轴

结构

分子式C18H13ClFN3

InChIKeyDDLIGBOFAVUZHB-UHFFFAOYSA-N

CAS号59467-70-8

关联

1,176

项与咪达唑仑相关的临床试验

NCT03223220 / Not yet recruiting临床2/3期IIT

Quelling of Excitotoxicity in Acute Stroke With Ketamine

The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.

开始日期2024-07-01

申办/合作机构-

IRCT20151221025641N8 / Suspended临床3期IIT

Comparison of the efficacy of oral and intranasal midazolam premedication on sedation before undergoing MRI in children

开始日期2024-06-04

申办/合作机构

Tehran University of Medical Sciences

CTRI/2024/05/067796 / Not yet recruitingN/AIIT

Comparative Evaluation of Oral Midazolam and Buccal Midazolam for Procedural Sedation in Anxious children during Local Anesthesia administration: A Cross over Clinical trial - NIL

开始日期2024-06-01

申办/合作机构-

100 项与咪达唑仑相关的临床结果

登录后查看更多信息

100 项与咪达唑仑相关的转化医学

登录后查看更多信息

100 项与咪达唑仑相关的专利（医药）

登录后查看更多信息

14,858

项与咪达唑仑相关的文献（医药）

2024-06-01·Journal of critical care

Multicentre implementation of a quality improvement initiative to reduce delirium in adult intensive care units: An interrupted time series analysis

Article

作者: Colaco, Heather ; Stelfox, Henry T ; Dyjur, Donalda ; Wickson, Patty ; Sinnadurai, Selvi ; Fiest, Kirsten M ; Redlich, Melissa ; Owen, Victoria S ; Faris, Peter D ; Harris, Jo ; Doig, Christopher J ; Zygun, David A ; Morrissey, Jeanna ; Niven, Daniel J ; O'Neill, Barbara ; Zuege, Danny J

PURPOSE:

The ABCDEF bundle may improve delirium outcomes among intensive care unit (ICU) patients, however population-based studies are lacking. In this study we evaluated effects of a quality improvement initiative based on the ABCDEF bundle in adult ICUs in Alberta, Canada.

MATERIAL AND METHODS:

We conducted a pre-post, registry-based clinical trial, analysed using interrupted time series methodology. Outcomes were examined via segmented linear regression using mixed effects models. The main data source was a population-based electronic health record.

RESULTS:

44,405 consecutive admissions (38,400 unique patients) admitted to 15 general medical/surgical and/or neurologic adult ICUs between 2014 and 2019 were included. The proportion of delirium days per ICU increased from 30.24% to 35.31% during the pre-intervention period. After intervention implementation it decreased significantly (bimonthly decrease of 0.34%, 95%CI 0.18-0.50%, p < 0.01) from 33.48% (95%CI 29.64-37.31%) in 2017 to 28.74% (95%CI 25.22-32.26%) in 2019. The proportion of sedation days using midazolam demonstrated an immediate decrease of 7.58% (95%CI 4.00-11.16%). There were no significant changes in duration of invasive ventilation, proportion of partial coma days, ICU mortality, or potential adverse events.

CONCLUSIONS:

An ABCDEF delirium initiative was implemented on a population-basis within adult ICUs and was successful at reducing the prevalence of delirium.

2024-05-01·Clinical pharmacology and therapeutics

Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling

Article

作者: Chen, Huijun ; Frechen, Sebastian ; Schultze-Mosgau, Marcus-Hillert ; Dallmann, André ; Francke, Klaus ; Kanefendt, Friederike ; Brase, Christine ; Liu, Tianxing

In the past, rifampicin was well‐established as strong index CYP3A inducer in clinical drug–drug interaction (DDI) studies. However, due to identified potentially genotoxic nitrosamine impurities, it should not any longer be used in healthy volunteer studies. Available clinical data suggest carbamazepine as an alternative to rifampicin as strong index CYP3A4 inducer in clinical DDI studies. Further, physiologically‐based pharmacokinetic (PBPK) modeling is a tool with increasing importance to support the DDI risk assessment of drugs during drug development. CYP3A4 induction properties and the safety profile of carbamazepine were investigated in two open‐label, fixed sequence, crossover clinical pharmacology studies in healthy volunteers using midazolam as a sensitive index CYP3A4 substrate. Carbamazepine was up‐titrated from 100 mg twice daily (b.i.d.) to 200 mg b.i.d., and to a final dose of 300 mg b.i.d. for 10 consecutive days. Mean area under plasma concentration‐time curve from zero to infinity (AUC(0‐∞)) of midazolam consistently decreased by 71.8% (ratio: 0.282, 90% confidence interval (CI): 0.235–0.340) and 67.7% (ratio: 0.323, 90% CI: 0.256–0.407) in study 1 and study 2, respectively. The effect was adequately described by an internally developed PBPK model for carbamazepine which has been made freely available to the scientific community. Further, carbamazepine was safe and well‐tolerated in the investigated dosing regimen in healthy participants. The results demonstrated that the presented design is appropriate for the use of carbamazepine as alternative inducer to rifampicin in DDI studies acknowledging its CYP3A4 inductive potency and safety profile.

2024-04-01·Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses

Dexmedetomidine – An Alternative to Midazolam in the Treatment of Ketamine-Induced Emergence Delirium: A Systematic Review

Review

作者: Smith, Korde ; Strickley, Trey ; Ericksen, Ashlee M

PURPOSE:

Analyze the effectiveness of dexmedetomidine compared to midazolam for the treatment of ketamine-induced emergence delirium in noncardiac surgical patients.

DESIGN:

Systematic review.

METHODS:

Guidelines outlined in the Preferred Reporting Items For Systematic Reviews and Meta-analyses (PRISMA)²² were used for this review. PubMed, Cumulative Index To Nursing And Allied Health Literature (CINAHL), MEDLINE, The Cochrane Library, EBSCOhost, National Institute of Health clinical trials, Google Scholar, and gray literature were searched for relevant studies. Only peer-reviewed nonexperimental studies, quasi-experimental studies, and randomized control trials with or without meta-analysis were included. The evidence was assessed using the Johns Hopkins Nursing Evidence-Based Practice guidelines for quality ratings and evidence level.

FINDINGS:

Five blinded randomized controlled trials, three quasi-experimental studies, and two retrospective nonexperimental studies comprised of 1,024 subjects were evaluated for this review. Dexmedetomidine was more effective at reducing ketamine-induced delirium in adult patients, although midazolam attenuated the psychomimetic effects of ketamine better in pediatric patients. Furthermore, postanesthesia care unit discharge times were similar between patients treated with dexmedetomidine and midazolam. The studies in this review were categorized as Level I, Level II, or Level III and rated Grade A, implying strong confidence in the actual effects of dexmedetomidine in all outcome measures of the review.

CONCLUSIONS:

The current evidence suggests that dexmedetomidine is an effective alternative for alleviating ketamine-induced delirium in noncardiac adult surgical patients. Multiple studies in this review noted improved hemodynamics and reduced postoperative analgesic requirements after administration of dexmedetomidine in conjunction with ketamine.

142

项与咪达唑仑相关的新闻（医药）

2024-06-26

·BioSpace

Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study

Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine intravenous (IV) Crossject’s bioequivalence study, recently published in Neurology and Therapy, remarkably consistent with RAMPART’s findings and authors’ views Dijon, France 26 June, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, provides additional, clinically meaningful perspectives on ZEPIZURE® in light of its recently published bioequivalence study results and of the conclusions and hints by the authors of the RAMPART (Rapid Anticonvulsant Medication Prior to ARrival Trial) study1, a landmark double-blind randomized clinical trial comparing the efficacy of IM midazolam vs. IV lorazepam in the pre-hospital treatment of status epilepticus by paramedics. Status epilepticus is defined as a seizure lasting more than 5 minutes. RAMPART unequivocally raised IM midazolam to the status of standard-of-care in the pre-hospital emergency management of status epilepticus by demonstrating its non-inferiority vs. IV lorazepam, as its primary endpoint. Moreover, IM midazolam demonstrated statistically significant superiority (p value<0.001) on the percentage of patients arriving in hospital seizure-free, which was 10% higher when using IM midazolam (329 out of 448 patients or 73.4% vs. 63.4% in the IV lorazepam 445-patient arm). These results underscored the importance of the speed of IM administration of midazolam, as an easy to store and pre-prepared medication for use by paramedics, features that were likely critical in driving efficacy in controlling seizures by the time of arrival in emergency departments. RAMPART was one of the largest studies every conducted in emergency settings, involving 4,314 paramedics, 33 EMS (Emergency Medical Services) units and 79 hospital ER (Emergency Room) departments across the U.S. It was supported by the National Institute of Health (NIH) and by the Biomedical Advanced Research and Development Authority (BARDA). The RAMPART study publication can be found here. Crossject’s study, recently published in the peer-reviewed journal Neurology and Therapy, positively echoed the benefits implied from RAMPART and is remarkably consistent with certain hints put forward by the authors in the RAMPART study. In Crossject’s study, ZEPIZURE® was equivalent to the IM injection from a syringe equipped with a 30mm needle (Dormicum®), and results also suggested a 2-fold lower variability as compared to that usually observed for routes of administration such as intranasal. With some vision and based on their experience then, RAMPART authors had highlighted a number of issues regarding intranasal solutions in epileptic seizures in general, and their prediction of the likely dominance of the IM route for the future. Today, no intranasal solution is approved for the management of status epilepticus. According to RAMPART’s authors, the upfront minutes were critical factors in driving the 10% superiority of IM midazolam, administered through traditional manual vial-form injectable, in positive clinical outcome by ER arrival. ZEPIZURE®, as an ultra-rapid two-step injection, strongly resonates in this practical interventional reality and is likely to further improve the speed of action by healthcare professionals and reliability in injecting a full dose of midazolam. Furthermore, in Crossject’s study, ZEPIZURE® enhanced the midazolam absorption during the very first few minutes post-injection, possibly resulting from the needle-free 50 milliseconds injection compared to manual IM and suggesting that seizure treatment may be efficient even sooner. Patrick Alexandre, CEO of Crossject added: “Beyond the 505(b)(2) regulatory and market gate for ZEPIZURE® into the arsenal available to healthcare professionals in status epilepticus episodes, as potentially the most rapid-to-use and lowest variability tool for the delivery of a complete midazolam dose pre-hospital, our product presents additional upside. ZEPIZURE®’s rapid and easy two-step application should potentially require limited training compared to traditional injectables, and its consistency in administering an effective dose would confer a key advantage. ZEPIZURE® is therefore poised to provide all patients, and their relatives or caregivers, with the professional standard-of-pre-hospital-care solution anytime and anywhere. Our team in Europe and the U.S. is now executing our development strategy to materialize these broad prospects, aiming to position ZEPIZURE® from a productivity contribution to healthcare professionals toward a high impact solution for all patients and families at risk of a broad range of epilepsy seizures.” About Crossject Crossject SA (Euronext: ALCJ; ) is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. Crossject is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The Company’s versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency medicines via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include mainly solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * Contract no: 75A50122C00031 with the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Research and Development Authority For further information, please contact: Investors Natasha Drapeau Cohesion Bureau +41 76 823 75 27 natasha.drapeau@cohesionbureau.com Media Sophie Baumont Cohesion Bureau +33 6 27 74 74 49 sophie.baumont@cohesionbureau.com 1Silbergleit et al. New England Journal of Medicine, February 2012. Clinicaltrials.gov NCT05026567 Attachment PR RAMDORM 25 June 2024_v9

临床结果临床研究

2024-06-24

·GlobeNewswire-Health Care

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce that AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial. AKYNZEO injection (Ready-to-Use) is a new method of administration and contains the same formulation as the prior AKYNZEO Injection (To-be-Diluted). The features of the new ready-to-use presentation of AKYNZEO injection include: No reconstitution or dilution required; infuse directly from the vial using a built-in hanging strapNo refrigeration required at any point during distribution, storage, or preparationAccessible via automated dispensing machine, allowing the product to be stored and available near the location of patient care AKYNZEO injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. It has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO injection does not contain polysorbate 80 or allergenic excipients such as soy or egg lecithin. It can be administered simultaneously with intravenous dexamethasone sodium phosphate. Dr. Melanie Rolli, Helsinn Group CEO, commented: “As a pioneer in cancer supportive care, Helsinn continues to be unwavering in our pursuit to help patients and clinicians in cancer care. We are very pleased to launch the new AKYNZEO Ready-to-Use vial, building on our legacy of innovation.” Ordering information Clinicians wishing to order the new vial should contact their GPO or distributor. The National Drug Code (NDC) number for AKYNZEO injection vial with hanger (Ready-to-Use) is 69639-106-01 and the J Code is J1454 (Injection, fosnetupitant 235 mg and palonosetron 0.25 mg); billing unit (single dose vial [SDV]). About AKYNZEO® AKYNZEO is the first and only 5-HT3 and NK1 receptor antagonists fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. A single dose of AKYNZEO given with dexamethasone has been shown to prevent chemotherapy-induced nausea and vomiting for up to 5 days. INDICATION AKYNZEO (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Limitations of Use AKYNZEO injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and fosnetupitant, a substance P/neurokinin-1 (NK-1) receptor antagonist: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. IMPORTANT SAFETY INFORMATION Warnings and Precautions Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT3 receptor antagonists.Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue AKYNZEO and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if AKYNZEO is used concomitantly with other serotonergic drugs. Adverse Reactions Most common adverse reactions (≥3%) for AKYNZEO capsules are headache, asthenia, dyspepsia, fatigue, constipation and erythema. The safety profile of AKYNZEO injection was generally similar to AKYNZEO capsules. Drug Interactions Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4. The plasma concentrations of CYP3A4 substrates can increase when co-administered with AKYNZEO. The inhibitory effect on CYP3A4 can last for multiple days Dexamethasone doses should be reduced when given with AKYNZEO. A more than two- fold increase in the systemic exposure of dexamethasone was observed 4 days after a single infusion of fosnetupitant.Consider the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) when administering with AKYNZEO. When administered with netupitant, the systemic exposure to midazolam was significantly increased. Avoid concomitant use of AKYNZEO in patients on chronic use of a strong CYP3A4 inducer such as rifampin as this may decrease the efficacy of AKYNZEO. Use in Specific Populations Avoid use of AKYNZEO in patients with severe hepatic impairment, severe renal impairment, or end-stage renal disease.Advise women of potential risk to fetus; limited data are available; may cause fetal harm. For more information about AKYNZEO® please see the full US Prescribing Information. About Helsinn Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology. Helsinn, headquartered in Lugano, Switzerland, has direct commercial operations in the U.S. and an extensive network of long-standing trusted partners enabling a commercial presence in more than 90 countries. Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. Helsinn is proud of its history of operating with great integrity, passion and quality. The company is committed to continuously striving for innovation for its patients and embracing sustainable growth as a core element of its strategic vision. To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and X. For more information: Helsinn Group Media Contact:Sabrina PerucchiGroup Communication ManagerLugano, Switzerland Tel: +41 (0) 91 985 21 21 Email: Info-hhc@helsinn.com

上市批准临床结果

2024-06-19

·蒲公英Ouryao

【山西】关于加强右美沙芬等药品管理通知

来源：山西药监局编辑：wangxinglai2004 2024年06月18日，山西药监局发布了《关于加强右美沙芬等药品管理工作的通知》，结合国家药监局发布相关要求，对生产、经营、使用等环节要求及时限进行了说明。各市市场监督管理局、综改区市场监督管理局，省局各检查分局、省药品检查中心、省药物警戒中心：根据《国家药监局、公安部、国家卫生健康委关于调整精神药品目录的公告》，自2024年7月1日起，右美沙芬（包括盐、单方制剂，下同）、纳呋拉啡（包括盐、异构体和单方制剂，下同）、氯卡色林（包括盐、异构体和单方制剂，下同）、含地芬诺酯复方制剂列入第二类精神药品目录；咪达唑仑原料药（包括盐、异构体，下同）和注射剂由第二类精神药品调整为第一类精神药品。根据《药品管理法》《麻醉药品和精神药品管理条例》等法律法规，结合精神药品目录调整和药品上市等情况，现将有关事宜通知如下：一、生产右美沙芬、咪达唑仑原料药和注射剂、含地芬诺酯复方制剂的药品生产企业应当按照《麻醉药品和精神药品管理条例》《关于印发〈麻醉药品和精神药品生产管理办法（试行）〉的通知》（国食药监安〔2005〕528号）有关规定，向省药品监督管理局申请相应品种的定点生产资格。生产右美沙芬、咪达唑仑的药品生产企业应当按规定申报2024年度生产需用计划。二、生产右美沙芬、纳呋拉啡、氯卡色林、咪达唑仑复方制剂的药品生产企业要按照《麻醉药品和精神药品生产管理办法（试行）》有关要求配备符合规定的储存条件和安全管理设施，制定采购、储存、生产、检验等环节的安全管理制度，按规定备案生产需用计划后方可组织生产。三、自2024年7月1日起，未取得相应品种定点生产资格和生产需用计划的企业不得生产右美沙芬、纳呋拉啡、氯卡色林、含地芬诺酯复方制剂、咪达唑仑原料药和注射剂。上述品种和复方制剂不得委托生产。四、右美沙芬、纳呋拉啡、含地芬诺酯复方制剂药品上市许可持有人、生产企业应当严格按照《药品注册管理办法》（国家市场监督管理总局第27号令）的规定办理相应药品标签、说明书的变更手续。自2024年10月1日起，所有生产出厂和进口的右美沙芬、纳呋拉啡、含地芬诺酯复方制剂必须在其标签和说明书上印有规定的标识。之前生产出厂和进口的上述品种在有效期内可继续流通使用。五、自2024年5月17日起，不具备第二类精神药品经营资质的药品经营企业不得再购进右美沙芬、纳呋拉啡、含地芬诺酯复方制剂，原有库存产品登记造册向所在地承担药品监督管理职责的部门报告后，按第二类精神药品有关规定售完为止；不具备第一类精神药品经营资质的药品经营企业不得再购进咪达唑仑注射剂，原有库存产品按原渠道退回。六、自2024年7月1日起，研制、购买、邮寄、运输和进出口右美沙芬、纳呋拉啡、氯卡色林、含地芬诺酯复方制剂、咪达唑仑原料药和注射剂应当符合《药品管理法》《麻醉药品和精神药品管理条例》有关精神药品管理要求。七、右美沙芬、纳呋拉啡、含地芬诺酯复方制剂的药品上市许可持有人、药品生产经营企业应当按照《药品管理法》等法律法规要求，建立并实施上述药品的追溯制度，按照规定提供追溯信息。医疗机构应当按照《药品管理法》等法律法规要求，提供药品追溯信息。八、各级药品监管部门要切实履行职责，加强麻精药品监管，及时通知辖区药品生产经营企业严格执行公告规定和本通知要求，监督企业落实麻醉药品和精神药品安全管理主体责任，加强右美沙芬等药品及其复方制剂的不良反应和药物滥用监测，严防流入非法渠道。

带量采购

100 项与咪达唑仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00550	-	N05CD08	DB00683

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
癫痫	美国	UCB, Inc.	2019-05-17
癫痫持续状态	日本	Alfresa Pharma Corp.	2014-09-26
镇静	中国	江苏恩华药业股份有限公司	1998-01-01
麻醉	日本	Maruishi Pharmaceutical Co., Ltd.	1988-03-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性反复发作	临床3期	美国	UCB Biopharma SRL	2014-05-01
慢性丙型肝炎	临床1期	中国	广东东阳光药业股份有限公司	2022-11-02
新型冠状病毒感染	临床1期	美国	Pfizer Inc.	2022-10-17
新型冠状病毒感染	临床1期	比利时	Pfizer Inc.	2022-10-17
晚期恶性实体瘤	临床1期	美国	AstraZeneca PLC	2021-10-15
肥胖	临床1期	美国	Pfizer Inc.	2020-12-15
心血管疾病	临床1期	英国	AstraZeneca PLC	2020-07-30
自闭症谱系障碍	临床1期	英国	Hoffmann-La Roche, Inc.	2020-07-15
自闭症	临床1期	英国	Hoffmann-La Roche, Inc.	2020-07-15
神经认知障碍	临床1期	英国	Hoffmann-La Roche, Inc.	2020-07-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04051827 (CTgov)	临床1期	晚期非小细胞肺癌	26	Midazolam (Part A: Midazolam Alone)	艱鹽淵夢獵簾範簾製壓(製窪淵壓鬱膚齋網齋觸) = 網艱範廠廠鏇廠窪鏇窪鹹壓簾鑰積構鹽簾憲願 (積構壓觸衊遞範衊窪積, 範願憲廠鑰憲鑰窪構鬱 ~ 鏇鬱醖範願製憲襯憲鹹) 更多	-	2024-04-12
				Midazolam+Mobocertinib (Part A: Midazolam + Mobocertinib)	艱鹽淵夢獵簾範簾製壓(製窪淵壓鬱膚齋網齋觸) = 鑰範醖觸鹹襯衊積築積鹹壓簾鑰積構鹽簾憲願 (積構壓觸衊遞範衊窪積, 廠壓構壓鏇獵鏇鬱選蓋 ~ 鏇衊構構廠淵網獵艱淵) 更多
NCT03815344 (CTgov)	临床4期	-	74	Standard-vaginal misoprostol (Standard)	淵壓觸窪淵製獵糧簾鹽(衊築遞範選醖願積積蓋) = 選醖窪獵獵餘壓鹹遞餘鏇遞築廠淵顧願範願鬱 (淵築壓壓鹹夢積淵蓋觸, 膚廠蓋糧餘網製廠鬱願 ~ 膚夢獵醖鬱鬱膚簾積淵) 更多	-	2024-01-09
				Standard-vaginal misoprostol+Standard (Standard-Vaginal Misoprostol)	淵壓觸窪淵製獵糧簾鹽(衊築遞範選醖願積積蓋) = 憲遞網繭淵艱鏇鑰製艱鏇遞築廠淵顧願範願鬱 (淵築壓壓鹹夢積淵蓋觸, 遞蓋鏇壓糧願鬱範衊窪 ~ 獵夢獵糧遞淵蓋鬱獵醖) 更多
NCT04068948 (CTgov)	临床4期	镇静 \| 龋齿	37	Meperidine+Hydroxyzine+Midazolam (Midazolam, Hydroxyzine, Meperidine)	顧繭範廠淵鏇鏇簾鏇壓(壓觸選醖壓鏇網齋鬱遞) = 鑰製糧鏇願淵範築鏇製遞齋廠簾範願獵衊積簾 (鬱構鹽襯鏇夢襯蓋構鹽, 壓遞構築糧餘淵簾鹽顧 ~ 衊鏇糧遞廠衊衊夢窪餘) 更多	-	2023-12-05
				Hydroxyzine+Midazolam (Midazolam, Hydroxyzine)	顧繭範廠淵鏇鏇簾鏇壓(壓觸選醖壓鏇網齋鬱遞) = 鬱膚廠淵衊觸醖襯壓遞遞齋廠簾範願獵衊積簾 (鬱構鹽襯鏇夢襯蓋構鹽, 餘鏇壓獵襯蓋網積艱鹽 ~ 築襯夢襯製壓襯構襯顧) 更多
NCT04621227 (CTgov)	临床1期	肥胖	16	Rosuvastatin (Rosuvastatin 10mg (Period 1))	齋鬱鑰壓構膚繭範鹽壓(遞糧簾窪糧築窪範淵壓) = 觸遞窪淵鬱糧壓顧夢鬱廠鏇齋衊觸鏇壓簾獵鏇 (網蓋築製衊艱繭鹹齋選, 淵觸衊觸廠簾鬱鬱蓋網 ~ 醖齋顧範積選膚壓築壓) 更多	-	2023-12-01
				Rosuvastatin+PF-06882961 (PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4))	齋鬱鑰壓構膚繭範鹽壓(遞糧簾窪糧築窪範淵壓) = 衊願願窪製襯鏇夢鏇廠廠鏇齋衊觸鏇壓簾獵鏇 (網蓋築製衊艱繭鹹齋選, 窪衊壓夢糧願淵鏇糧齋 ~ 觸窪壓窪醖觸鏇繭壓積) 更多
NCT05032950 (CTgov)	临床1期	新型冠状病毒感染	12	Midazolam (Midazolam 2 mg)	選衊壓選製壓獵鬱鑰憲(廠獵襯鑰遞鬱鏇憲艱顧) = 鹹製淵衊衊構夢醖壓遞築鹽築餘蓋膚鹽膚鬱憲 (顧壓醖鑰製遞鹽窪築製, 糧製齋製築蓋顧鑰鹽願 ~ 網廠窪窪範齋蓋鹹壓壓) 更多	-	2023-10-04
				PF-07321332+Midazolam+Ritonavir (PF-07321332 300 mg/Ritonavir 100 mg + Midazolam 2 mg)	選衊壓選製壓獵鬱鑰憲(廠獵襯鑰遞鬱鏇憲艱顧) = 膚蓋壓壓選膚憲鏇衊顧築鹽築餘蓋膚鹽膚鬱憲 (顧壓醖鑰製遞鹽窪築製, 築簾糧淵獵壓膚鹹餘憲 ~ 願構積製觸壓範壓積鏇) 更多
NCT03420742 (CTgov)	临床1期	肿瘤 \| ALK阳性实体瘤	24	Midazolam (Part A, Cycle 1 Day 1: Midazolam Alone)	遞醖鹽選憲醖獵鹽觸積(繭壓鏇製製艱淵鹹觸遞) = 廠壓廠選範襯餘簾顧選範顧蓋遞範積襯餘憲範 (廠範齋鏇鬱積鑰積蓋淵, 鹹積網衊醖夢願觸艱憲 ~ 餘鬱衊選繭窪壓壓齋憲) 更多	-	2023-01-27
				Midazolam+Brigatinib (Part A, Cycle 1 Day 21: Midazolam + Brigatinib)	遞醖鹽選憲醖獵鹽觸積(繭壓鏇製製艱淵鹹觸遞) = 鬱壓鹽艱網簾糧鹽艱積範顧蓋遞範積襯餘憲範 (廠範齋鏇鬱積鑰積蓋淵, 網夢膚憲簾齋繭範遞糧 ~ 鬱糧遞窪艱衊廠鹽製願) 更多
Pubmed	临床1期	ALK阳性实体瘤	-	Brigatinib	鑰積範選願構襯憲壓築(築壓網夢願獵淵範蓋衊) = 構獵鑰顧鏇遞壓壓積繭範淵淵遞餘襯廠構製糧 (鹽糧範顧鹽積顧選顧廠 ) 更多	-	2022-12-29
ChiCTR1800015038 (Pubmed)	N/A	镇静	156	3 ug/kg intranasal DEX plus 0.2 mg/Kg oral midazolam	構構遞夢遞構鏇淵淵鑰(製壓繭淵糧選蓋願顧鑰) = 願蓋壓簾淵築簾積廠獵網鏇範夢蓋窪襯鹽鑰製 (醖積鬱蓋廠糧範壓艱鬱 ) 更多	-	2022-11-23
				2 ug/kg intranasal DEX plus 0.2 mg/Kg oral Midazolam	構構遞夢遞構鏇淵淵鑰(製壓繭淵糧選蓋願顧鑰) = 醖夢獵積襯餘夢範願窪網鏇範夢蓋窪襯鹽鑰製 (醖積鬱蓋廠糧範壓艱鬱 ) 更多
NCT03813121 (CTgov)	临床1/2期	烟草依赖	10	placebo intravenous infusion (Placebo Intravenous Infusion)	壓網獵簾鑰夢積顧餘窪(獵膚衊積製選築願簾壓) = 淵鏇蓋襯鏇窪壓鑰築廠製衊網繭淵築鹹廠築膚 (顧鹹繭蓋艱鹽鹹鏇憲壓, 壓艱鬱鑰齋蓋鑰窪齋蓋 ~ 糧衊壓壓鬱觸願餘膚構) 更多	-	2022-06-02
				ketamine intravenous infusion (Ketamine Intravenous Infusion)	壓網獵簾鑰夢積顧餘窪(獵膚衊積製選築願簾壓) = 遞鬱鹽衊憲積選鬱餘齋製衊網繭淵築鹹廠築膚 (顧鹹繭蓋艱鹽鹹鏇憲壓, 鏇遞齋顧壓壓遞窪積艱 ~ 壓鬱憲鑰淵鹽獵鏇製憲) 更多